Malignant fibrous histiocytoma of the right upper leg – A case report

Maligni fibrozni histiocitom desne natkolenice


Clinical Center Kragujevac, *Clinic for General and Thoracic Surgery, †Department of Pathology, ‡§Department of Anesthesiology and Reanimatology, Kragujevac, Serbia; University of Kragujevac, †Faculty of Medical Sciences, ‡Department of Anatomy, Kragujevac, Serbia; Military Medical Academy, †Clinic for General Surgery, Belgrade, Serbia; University of Defence, †Faculty of Medicine of the Military Medical Academy, Belgrade, Serbia

Abstract

Introduction. Malignant fibrous histiocytoma is a fast spreading pleomorphic sarcoma with a high malignant potential. Its spreading is characterized with local invasion and distant metastases with early onset. Most common localisations of development are extremities, trunk and retroperitoneum. Given the current status, discuss putative etiology, histopathology with findings and intraoperative documentation, we presented malignant fibrous histiocytoma.

Case report. We presented a 56-years-old female Serbian with tumor in the thigh that clinically resembles incapsulated hematoma. Computed tomography revealed intramuscular tumor with a heterodense structure and compression on surrounding tissue. Ex tempore biopsy specimen showed malignant potential of the tumor. Wide and radical excision of the nodule has been done, and definitive histopathological verification revealed malignant fibrous histiocytoma.

Conclusion. Malignant fibrous histiocytoma is a most common type of soft tissue sarcomas in adults. Frequent localization is on lower extremities, and every rapidly enlarging nodule in this localization that on computed tomography is like incapsulated hematoma with necrotic zone should alert suspicion on presence of this type of sarcoma.

Key words:
sarcoma; soft tissue neoplasms; diagnosis; histological techniques; surgical procedures, operative.

Introduction

Malignant fibrous histiocytoma (MFH) is a most common type of soft tissue sarcomas (STS), that was originally described by Ozzello et al.1 in 1963 and O’Brien and Stout2 in 1964. World Health Organization (WHO) defined MFH as an undifferentiated high grade pleomorphic sarcoma.3 It is the most common soft tissue sarcoma in adults, arising

Apstrakt

Uvod. Maligni fibrozni histiocitom je pleomorfni sarkom visokog malignog potencijala koji se brzo širi. Karakteriše se širenjem lokalnom invazijom i ranom pojavom udaljenih metastaza. Najčešće lokalizacije su ekstremiteti, trup i retroperitoneum. S obzirom na redak preparat, nedovoljno jasnu etiologiju i mehanizme nastanka ove bolesti, kao i adekvanj patohistološki nalaz i intraoperativni prikaz, cilj ovog prikaza je bio da se ukaze na trenutna saznanja o ovoj bolesti, njoj etiologiji, patohistološkim karakteristikama, diferencijalnoj dijagnozi i lečenju.

Prikaz bolesnika. Prikazana je bolesnica, stara 56 godina, sa tumorom desne raktolerice koji se klinički prezentovao kao inkapsulirani hematom. Kompijerizator-vanom tomografijom utvrđeno je da se radi o intramuskularnom tumoru koji se komprimovao u okolne strukture. Ex tempore biopsija je ukazala na maligni potencijal tumor. Urađena je široka i radikalna ekscizija promene, a definitivni patohistološki nalaz pokazao je da se radi o malignom fibroznom histiocitomu.

Zaključak. Maligni fibrozni histiocitom predstavlja najčešći tip sarkoma mekih tkiva kod odraslih. Često je lokalizovan na donjim ekstremitetima. Svaki brzorastući tumefakt mekih tkiva donjih ekstremiteta, koji na snimci kompijerizovane tomografije podsjeća na inkapsulirani hematom sa zonama nerekne, treba da pobudi sumnju na maligni fibrozni histiocitom.
most frequently during the sixth and seventh decades of life 4. Localisation regarding on the region of the body is as follows: over 70% of cases are located on extremities (50% on lower, and 25% on upper), followed by retroperitoneum (15%), and head and neck in 3–10% 5. Rare cases include almost every organ in the body – bones, lungs, intestine, greater omentum, scars after surgical incision or even retained gauze 6. MFH on extremities presents as a slow growing painless mass, while presentation in retroperitoneum is non-specific: appetite and body weight loss, fever and discomfort. It has a great malignant potential, with extensive local spreading and early onset of distant metastases 7. Regarding on data above, every primary malignant tumor of extremities or retroperitoneum localisation, in people older than 45 years, should be considered as MFH. Recent studies indicate that most probable cells of origin are primitive mesenchimal cells or fibroblastic cells, that have characteristics both of fibroblasts and histiocytes 8. Given the line of rare case and specimen, lack of a clear etiology, molecular and genetic mechanisms of this disease, we presented literature review, histopathologic findings with variant morphology, intraoperative documentation and modalities of treatment applied to the patient with MFH.

**Case report**

A 56-year-old female was admitted to our Clinic with the mass in the front of the right thigh. On physical examination firm tumor with positive fluctuation phenomenon was found and initially impressed like an incapsulated hematoma. Incision was done and material was sent to an *ex tempore* biopsy, which confirmed malignant nature of the mass. Standard blood tests and chest x-rays were normal. Preoperative computed tomography of the right thigh revealed intramuscular tumor (size $65 \times 64 \times 11$ mm), that suppressed surrounding structures. It was of a heterodense structure, peripherally with intensive post-contrast opacification and internally with greater zone of necrosis. Ipsilateral inguinal region and bones tomography were normal (Figure 1).

In general anesthesia, wide local excision and Redon drainage of the wound was done (Figure 2). As expected, patient recovered uneventfully.

**Histopathology**

Operating material was sent for histopathologic analysis. Grossly, the tumor at the intersection was of whitish color, vitreous luster, with yellowish areas of necrosis and hemorrhage. Tumor samples were fixed in formalin, embedded in paraffin, cut into the cryotome in 4 µ thick tissue sections and stained with standard hematoxylin and eosine (HE) staining method. Microscopically, the tumor showed a classic image of a giant cell type MFH. It was built out from...
the storiform arranged connective cells, along with zones dominated by histiocytes, among which there were numerous multinucleated giant osteoclast type cells (Figure 3).

Discussion

MFH is a group of pleomorphic neoplasm that have similar morphological characteristics. There are many different histopathological images which can be grouped into 4 subtypes, according to the new WHO classification. MFH subtypes are: 1) undifferentiated pleomorphic MFH; the largest part, about 65% of MFH, belongs to this group, which are typically composed of a mixture of spindle, polygonal and round cells found in a storiform matrix; it is usually localized to lower extremities and the retroperitoneum mainly in the elderly; 2) myxoid MFH is also common, occurring in 10–20% of cases. It is characterized by myxoid matrix that can be seen under the microscope, otherwise referred to as myxofibrosarcoma and can occur in two forms: superficial and deep 5; 3) MFH with giant cell variant is less common, occurring in 10–15% of cases of this type. It is characterized by the existence of multinucleate giant cells that can be seen under a microscope; 4) inflammatory MFH is the rarest form, occurring in only 5–8% of cases. Its characteristic is the existence of intensive inflammatory infiltrate predominantly consisting of neutrophils, lymphocytes and sparkling or anaplastic histiocytes, mainly in the retroperitoneum 10. Angiomatoid MFH was considered as the fifth subtype, but no longer because histologically has similarities with blood vessels, low malignant potential and gives rare metastasis 11–14. In the new WHO classification this type is marked as angiomatoid fibrous histiocytoma. MFH is an aggressive sarcoma, with extensive local spreading and early distant metastases. It has been determined to exhibit high-grade and biological aggressiveness.

Tumor location, size, and histologic grade directly influence prognosis of MFH. Most commonly metastases occur in the lungs (90%), lymph nodes (12%), bone (8%), and liver (1%) 15. The incidence of regional lymph node involvement is up to 15% 7, 16.

Risk factors for development of MFH have not been clearly established. Exposure to the ionizing radiation, especially in the MFH of the head and neck, can develop alternative mutations in this tumor. Infarction of the bone is another well-known risk factor 17, 18. Genetic alterations of the p53 gene is often linked with a poorer prognosis 19, and frequent deletions on...
Diagnosis

The diagnosis of MFH is not easy to establish. The presence of the disease may be suspected and the diagnosis can be set on the basis of the following methods: conventional (native) radiography – MFH is seen as a non-specific calcified tissue mass, or can be seen as compression or erosion of the surrounding tissue; echosonography (EHO) – seen as well-defined mass that has a complex internal scheme, heteroechogetic structures with echogenic areas representing the zone of necrosis; CT – MFH is seen as a non-specific calcified tissue, or can be seen as compression or erosion of the surrounding structures; PET/CT scanning is useful on assessing metastases. On angiography scans MFH is seen as a zone of hypervascularisation.

A biopsy has an important place in the diagnosis of MFH. It can be open and needle biopsy. Open biopsy is linked with a higher risk of complications, or less likely diagnoses for nos, while in case of the needle biopsy there are opposite results. Sentinel lymph node biopsy is an effective method for evaluating regional disease.

For the histologic diagnosis conventional microscopic picture of MFH on standard HE stained tissue sections is usually sufficient. Alternation of storiform arrangements with connective cells and areas dominated by histiocytes, with variations in presence of giant cells, inflammatory infiltrate, fields of miocyt degeneration or proliferation of blood vessels, depending on the histological subtype of MFH, means that MFH has a potential for bilateral differentiation. In atypical cases, as an additional method, immunohistochemistry is used, excluding other types of sarcoma by using a broad-spectrum of antibodies of mesenchymal differentiation. Neoplastic cells are positive on vimentin in about 50% of the epithelial membrane antigen (EMA) and desmin, smooth muscle actin (SMA) and rarely on calponin, but still negative on cytokeratins and protein S-100. The pre-B cell antigen LN-2 (CD74) is a marker which helps distinguish MFH from atypical fibroxanthoma (AFX). The presence of immunohistochemical marker, bone morphogenic protein 2, gives better prognosis for patients. Focal or weak immunoreactivity to mesenchymal markers such as CD10, CD99, CD68, lysozyme, fascin, and other intermediated filaments like desmin and neurofilaments has already been observed in cases of MFH.

Treatment

The goal of treatment is wide surgical resection of the tumor with clear resection margins. The most common form of surgical treatment is the early and complete surgical excision with en bloc lymph dissection. In some cases, as a therapeutic option for the solution of MFH, amputation of limb is considered. After tumor resection, as an integral part of the surgical treatment reconstructive procedures are followed. Studies in last two decades have demonstrated that conservative surgery, with or without adjuvant therapy, appears to be an effective treatment for sarcomas, including high-grade sarcomas, with a local recurrence rate of 7–15%, with no significant differences in terms of overall survival and disease-free interval compared with amputation.

After surgery, chemotherapy is usually applied – doxorubicin, or gemcitabine or a combination of doxorubicin and dacarbazine, and doxorubicin, ifosfamide and mesna. MFH treatment protocols depend on several factors: the size of the primary lesion, metastasis, localization near the vascular or visceral structures, patient’s age, general condition. The basic method of treatment is radical surgery: complete removal of tumor and surrounding structures, while in those tumors that are localized near the vascular and nerve elements marginal surgical excision through the fibrous tissue that surrounds sarcoma is performed. Oncology goal of surgery is to achieve clean edges with no tumor cells.

Irradiation is carried out with the aim of reducing the probability of local recurrence and metastasis. It may be preoperative, intraoperative and postoperative. The dose of radiation ranges from 40–65 Gy and depends on the extensiveness of surgical treatment, localization of resection edges and whether they contain or not microscopic or macroscopic tumor cells.

Chemotherapy protocol that is used in the treatment is referred to as mesna, doxorubicin, ifosfamide, and dacarbazine (MAID). So far, chemotherapy is employed only for widespread disease, but large trials have not shown a significant benefit. Multiple tyrosine kinase inhibitor, sunitinib, for MFH is currently undergoing a phase II trial, and phase I trial investigating ipilimumab in the treatment of MFH is in progress.

A characteristic of MFH is an increased incidence of local recurrence of the disease. Neoplastic infiltration of the resection margins at the end of surgery appears to be among the major factors affecting the rate of local recurrence. In fact, the local recurrence rate approximates 13% with margins of < 1 cm, while it may be reduced to 0% in cases with margins more than 1 cm. Previous studies have shown that 19–64% of patients with MFH developed local recurrences. The recurrence rate of MFH in extremities was lower than that in other areas. Local recurrence rates in extremities have been reported to be 19–38%, factors that indicate a poor prognosis are lesions over 5 cm, positive edges and local recurrence, while the most important prediction factor for distant metastasis is the size of the primary lesion, especially over the size of 5 cm.

The general outcomes of extremity MFHs are superior to those of head and neck and retroperitoneal MFHs. According to a study conducted by Chen et al., 5-year survival rate is 76.2%. Clinical outcomes of extremity MFHs are associated with multiple factors. A French multicenter study of 410 patients with soft tissue sarcoma showed that tumor staging, resection margin, tumor location, histology type, and age of the patients are independent predictors of 5-year survival. In regard of the size of the tumor, 5-year

survival for tumors < 5 cm is 82%, then falls to 68% for 5- to 10-cm tumors, and 51% for tumors >10 cm. 24, 33.

Conclusion

MFH represents a rare and mysterious type of STS that requires timely diagnosis and aggressive treatment approach. For better survival results it is necessary to re-examine and adopt treatment protocols, especially with new biological agents and molecular – targeted therapy. Adjuvant therapy should be individually based. Understanding etiology, pathogenesis and genetic mechanisms that leads to this disease still remains controversial.

Acknowledgement

The part of this research is supported by Ministry of Education, Science and Technological Development of the Republic of Serbia, Grants III41007 and III41010.

References


Received on May 12, 2016.
Revised on September 08, 2016.
Accepted on September 12, 2016.
Online First September, 2016.